Are you Dr. Adelglass?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 36 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
6020 W Parker Rd
Ste 400
Plano, TX 75093Phone+1 972-492-6990Fax+1 972-394-4405
Summary
- Dr. Jeffrey Adelglass, MD is an otolaryngologist in Plano, Texas. He is currently licensed to practice medicine in Texas, Nevada, and Florida. He is affiliated with Texas Health Center for Diagnostic & Surgery and Texas Health Presbyterian Hospital Plano.
Education & Training
New York Presbyterian Hospital (Columbia and Cornell Campus)Residency, Otolaryngology - Head and Neck Surgery, 1977 - 1980
Universidad Autonoma de GuadalajaraClass of 1975
Certifications & Licensure
NV State Medical License 2020 - 2025
TX State Medical License 1981 - 2024
FL State Medical License 1988 - 2002
NY State Medical License 1978 - 1992- American Board of Otolaryngology - Head and Neck Surgery Otolaryngology
Awards, Honors, & Recognition
- Fellow (FACS) American College of Surgeons
Clinical Trials
- Safety, Pharmacokinetics, and Efficacy Study of NB-001 to Treat Recurrent Herpes Labialis Start of enrollment: 2007 Feb 01
- Emervel® Deep Lidocaine vs. Juvederm® Ultra Plus in Treatment of Moderate to Severe Facial Wrinkles and Folds Start of enrollment: 2010 Sep 27
- Topical Application of Cocaine HCl 4% and 10% on Safety and Efficacy in Local (Topical) Anesthesia Start of enrollment: 2014 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsImmunogenicity and safety of NVX-CoV2373 as a booster: A phase 3 randomized clinical trial in adults.Fritz Raiser, Matthew Davis, Jeffrey Adelglass, Miranda R Cai, Gordon Chau
Vaccine. 2023-09-22 - 26 citationsSafety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents: A Randomized Clinical Trial.Germán Áñez, Lisa M Dunkle, Cynthia L Gay, Karen L Kotloff, Jeffrey M Adelglass
JAMA Network Open. 2023-04-03 - 223 citationsEfficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico.Lisa M Dunkle, Karen L Kotloff, Cynthia L Gay, Germán Áñez, Jeffrey M Adelglass
The New England Journal of Medicine. 2022-02-10
Press Mentions
Novavax COVID-19 Phase 3 Trial in North TexasDecember 29th, 2020
Synexus Espande La Propria Capacità Globale E Debutta Nel Mercato Statunitense Con L'acquisizione Di Research Across AmericaMarch 1st, 2016- Synexus Espande La Propria Capacità Globale E Debutta Nel Mercato Statunitense Con L'acquisizione Di Research Across AmericaMarch 1st, 2016
- Join now to see all
Professional Memberships
- Member
